Clene shares surge 20.42% premarket on JonesTrading buy rating for CNM-Au8 driven by promising ALS results.

miércoles, 12 de noviembre de 2025, 8:20 am ET1 min de lectura
CLNN--
Clene Inc. surged 20.42% in premarket trading following a bullish analyst rating from JonesTrading. Analyst Justin Walsh reiterated a Buy rating for Clene’s CNM-Au8 program, maintaining a $30.00 price target, which aligns with the stock’s sharp premarket rise. The analyst’s endorsement of the ALS-focused therapy highlights renewed investor confidence in the company’s pipeline, directly supporting the upward price movement.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios